Connection
Dmitri Simberg to Doxorubicin
This is a "connection" page, showing publications Dmitri Simberg has written about Doxorubicin.
|
|
Connection Strength |
|
 |
|
 |
|
2.816 |
|
|
|
-
Li Y, Ettah U, Jacques S, Gaikwad H, Monte A, Dylla L, Guntupalli S, Moghimi SM, Simberg D. Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin. Mol Pharm. 2024 Jun 03; 21(6):3053-3060.
Score: 0.790
-
Li Y, Lofchy L, Wang G, Gaikwad H, Fujita M, Simberg D. PEGylated Liposomes Accumulate in the Areas Relevant to Skin Toxicities via Passive Extravasation across "Leaky" Endothelium. ACS Nano. 2022 Apr 26; 16(4):6349-6358.
Score: 0.681
-
Benasutti H, Wang G, Vu VP, Scheinman R, Groman E, Saba L, Simberg D. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population. Bioconjug Chem. 2017 11 15; 28(11):2747-2755.
Score: 0.502
-
Griffin JI, Wang G, Smith WJ, Vu VP, Scheinman R, Stitch D, Moldovan R, Moghimi SM, Simberg D. Revealing Dynamics of Accumulation of Systemically Injected Liposomes in the Skin by Intravital Microscopy. ACS Nano. 2017 11 28; 11(11):11584-11593.
Score: 0.501
-
Li Y, Saba L, Scheinman RI, Banda NK, Holers M, Monte A, Dylla L, Moghimi SM, Simberg D. Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts. ACS Nano. 2024 10 22; 18(42):28649-28658.
Score: 0.203
-
Gifford G, Vu VP, Banda NK, Holers VM, Wang G, Groman EV, Backos D, Scheinman R, Moghimi SM, Simberg D. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. J Control Release. 2019 05 28; 302:181-189.
Score: 0.139
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|